BTBenjamin J. Tuck

Benjamin J. Tuck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benjamin J. Tuck has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perforin-2 is a pore-forming effector of endocytic escape in cross-presenting dendritic cells

    by Pablo Rodríguez-Silvestre, Marco Laub, Patrycja A. Krawczyk, Alexandra K. Davies, Julia P. Schessner, Reejuana Parveen, Benjamin J. Tuck, William A. McEwan, Georg H. H. Borner, Patrycja Kozik

    During initiation of antiviral and antitumor T cell–mediated immune responses, dendritic cells (DCs) cross-present exogenous antigens on major histocompatibility complex (MHC) class I molecules. Cross-presentation relies on the unusual “leakiness” of endocytic compartments in DCs, whereby internalized proteins escape into the cytosol for proteasome-mediated generation of MHC I–binding peptides. Given that type 1 conventional DCs excel at cross-presentation, we searched for cell type–specific effectors of endocytic escape. We devised an assay suitable for genetic screening and identified a pore-forming protein, perforin-2 ( Mpeg1 ), as a dedicated effector exclusive to cross-presenting cells. Perforin-2 was recruited to antigen-containing compartments, where it underwent maturation, releasing its pore-forming domain. Mpeg1 −/− mice failed to efficiently prime CD8 + T cells to cell-associated antigens, revealing an important role for perforin-2 in cytosolic entry of antigens during cross-presentation.


  • Open Access

    Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models

    by Aamir S. Mukadam, Lauren V. C. Miller, Annabel E. Smith, Marina Vaysburd, Siri A. Sakya, Sophie Sanford, Sophie Keeling, Benjamin J. Tuck, Taxiarchis Katsinelos, Chris Green, et al.

    Aggregates of the protein tau are proposed to drive pathogenesis in neurodegenerative diseases. Tau can be targeted by using passively transferred antibodies (Abs), but the mechanisms of Ab protection are incompletely understood. In this work, we used a variety of cell and animal model systems and showed that the cytosolic Ab receptor and E3 ligase TRIM21 (T21) could play a role in Ab protection against tau pathology. Tau-Ab complexes were internalized to the cytosol of neurons, which enabled T21 engagement and protection against seeded aggregation. Ab-mediated protection against tau pathology was lost in mice that lacked T21. Thus, the cytosolic compartment provides a site of immunotherapeutic protection, which may help in the design of Ab-based therapies in neurodegenerative disease.


  • Open Access

    Tau assemblies enter the cytosol in a cholesterol sensitive process essential to seeded aggregation

    by Benjamin J. Tuck, Lauren V. C. Miller, Emma L. Wilson, Taxiarchis Katsinelos, Shi Cheng, Marina Vaysburd, Claire Knox, Lucy Tredgett, Emmanouil Metzakopian, Leo C. James, et al.

    Accumulating evidence supports a prion-like mechanism in the spread of assembled tau in neurodegenerative diseases. Prion-like spread is proposed to require the transit of tau assemblies to the interior of neurons in order to seed aggregation of native, cytosolic tau. This process is poorly understood and remains largely hypothetical. Here, we develop sensitive techniques to quantify the cytosolic entry of tau in real-time. We find that tau does not promote its own entry but, rather, is wholly dependent on cellular machinery. We find that entry to the widely used reporter cell line HEK293 requires clathrin whereas entry to neurons does not. Cholesterol depletion or knockdown of cholesterol transport protein Niemann-Pick type C1 in neurons renders cells highly vulnerable to cytosolic entry and seeded aggregation. Our findings establish entry as the rate-limiting step in seeded aggregation and demonstrate that dysregulated cholesterol, a feature of several neurodegenerative diseases, potentiates tau aggregation. Graphical